

Clinical trials of warfarin low dose

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
warfarin low dose vs control			
BAATAF (warfarin vs no treatment) , 1990 [NCT00000517] n=212/208 follow-up: 2.2 years	warfarin low dose (target INR:1.5-2.7) versus no placebo.people received no treatment but could choose to take aspirin.	non rheumatic AF	Parallel groups Open
warfarin low dose + aspirin vs control			
SAFT(warfarin low dose + aspirin vs no treatment) , 2003 n=334/334 follow-up: 33 months	warfarin low dose (1.25 mg/d) + aspirin 75 mg/d versus no treatment	Low-medium risk patients with non valvular atrial fibrillation.	Parallel groups Open Sweden
warfarin low dose vs placebo			
SPINAF (warfarin vs placebo) , 1992 n=260/265 follow-up: 1.75 years	warfarin low dose(target INR 1.4-2.8) versus placebo	men ,with chronic nonrheumatic atrial fibrillation	Parallel groups Double blind usa
warfarin low dose vs warfarin standard dose			
AFASAK II (warfarin low dose vs warfarin standard dose) , 1998 n=167/170 follow-up: 3.5 years	warfarin fixed low dose (1.25 mg/d) versus warfarin standard dose(target INR 2-3)	chronic non valvular atrial fibrillation	Parallel groups Open Denmark
MWNAF , 1998 n=150/153 follow-up: 14.5 months	warfarin low dose (1.25mg/d) versus warfarin standard dose(target INR 2.0-3.0)	Patients over 60 with non rheumatic atrial fibrillation	Parallel groups Open Italy

More details and results :

- antithrombotics for atrial fibrillation in primary prevention of thromboembolic events at <http://www.trialresultscenter.org/go-Q57>

References

BAATAF (warfarin vs no treatment), 1990:

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators *N Engl J Med*. 1990 Nov 29;323(22):1505-11 [[2233931](#)]

SAFT(warfarin low dose + aspirin vs no treatment), 2003:

Edvardsson N, Juul-Moller S, Omblus R, Pehrsson K Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. *J Intern Med* 2003 Jul;254:95-101 [[12823646](#)]

Edvardsson N, Juul-Moller S, Omblus R, Pehrsson K Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. *J Intern Med* 2003 Jul;254:95-101 [[12823646](#)]

SPINAF (warfarin vs placebo), 1992:

Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. *N Engl J Med* 1992 Nov 12;327:1406-12 [[1406859](#)]

AFASAK II (warfarin low dose vs warfarin standard dose), 1998:

Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. *Arch Intern Med* 1998 Jul 27;158:1513-21 [[9679792](#)]

MWNAF, 1998:

Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, John N, Noventa F, Dalla Volta S Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. *Am J Cardiol* 1998 Aug 15;82:433-7 [[9723629](#)]

Entry terms: warfarin